Bionano Genomics' stock experienced an after-hours plunge of 9.38% on Wednesday, following the company's announcement of the effective date for a reverse stock split.
The biotechnology company, focused on genome analysis solutions, stated that its previously approved reverse stock split had become effective. This corporate action typically results in a decrease in the total number of outstanding shares and a corresponding increase in the stock's trading price.
While reverse stock splits do not fundamentally change a company's market capitalization or business operations, the initially higher stock price following the split can sometimes lead to a short-term sell-off by investors reacting to the cosmetic change.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.